Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma

Publication

Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma

Journal Paper/Review - Apr 28, 2008

Piguet Anne-Christine, Semela David, Keogh Adrian, Wilkens Ludwig, Stroka Deborah, Stoupis Christoforos, St-Pierre Marie V, Dufour Jean-François

Citation

Piguet A, Semela D, Keogh A, Wilkens L, Stroka D, Stoupis C, St-Pierre M, Dufour J. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol 2008; 49:78-87.

Type

Journal Paper/Review (English)

Journal

J Hepatol 2008; 49

Publication Date

Apr 28, 2008

Issn Print

0168-8278

Pages

78-87

Brief description/objective

Hepatocellular carcinoma (HCC) is resistant to chemotherapy. We reported that sirolimus, an mTOR inhibitor, has antiangiogenic properties in HCC. Since antiangiogenic therapy may enhance chemotherapy effects, we tested the antitumorigenic properties of sirolimus combined with doxorubicin in experimental HCC.